Grifols, S.A. (GRF.MC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thomas H. Glanzmann | Executive Chairman | 1.9M | -- | 1958 |
| Mr. Jose Ignacio Abia Buenache | CEO & Director | -- | -- | 1968 |
| Mr. Alfredo Arroyo Guerra | CFO & VP | -- | -- | 1958 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | -- | -- | 1983 |
| Ms. Nuria Pascual Lapeña | VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer | -- | -- | 1964 |
| Mr. David Ian Bell | Chief Corporate Development, Legal & Data Protection Officer | -- | -- | 1954 |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer | -- | -- | 1965 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | -- | -- | 1981 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | -- | -- | 1961 |
| Mr. Sergio Roura Adell | President of Commercial Tech Support | -- | -- | 1968 |
Grifols, S.A.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 23,744
Description
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Corporate Governance
Recent Events
- Jun 03, 2021Ex-Dividend Date